Farxiga (Dapagliflozin) Cost in Michigan: Prices, Insurance, and Savings for 2026

What Does Farxiga Actually Cost at a Michigan Pharmacy in 2026?

Without insurance or discount cards, a 30-day supply of brand-name Farxiga 10 mg costs approximately $620 at Michigan retail pharmacies. That figure tracks the AstraZeneca wholesale acquisition cost and varies only modestly across chains like Meijer, CVS, Rite Aid, and independent pharmacies throughout the state.

The $620 figure is the manufacturer list price, sometimes called the "sticker price." Few patients pay the full amount. What you owe depends on your insurance tier, deductible status, and whether you use a manufacturer coupon or pharmacy discount aggregator. A patient with a Blue Cross Blue Shield of Michigan PPO plan on a preferred formulary tier might see a copay between $30 and $75. A patient in the deductible phase of a high-deductible health plan could face the full $620 until the deductible is met.

Price-comparison platforms such as GoodRx and RxSaver list Michigan-specific cash prices that sometimes dip below $550, but these fluctuate weekly. The FDA approved dapagliflozin (Farxiga) in January 2014 for type 2 diabetes, expanded the label to heart failure with reduced ejection fraction in May 2020, and added chronic kidney disease in April 2021 1. No AB-rated generic exists yet, which keeps the retail price anchored near the AstraZeneca list.

Michigan residents filling at mail-order pharmacies (Express Scripts, Optum Rx, or Costco mail) can occasionally save 5 to 15% over brick-and-mortar retail. Ask your plan about 90-day mail fills; the per-unit cost often drops when the supply doubles or triples.

Michigan Medicaid Coverage for Farxiga

Michigan Medicaid does cover Farxiga, but only after prior authorization. Your prescriber must document a clinical rationale and, in many cases, show that metformin was tried first or is contraindicated before the Michigan Department of Health and Human Services (MDHHS) pharmacy benefit team will approve the claim.

For type 2 diabetes, the Medicaid preferred drug list (PDL) usually favors metformin and sulfonylureas as first-line agents. SGLT2 inhibitors like dapagliflozin sit in a prior-authorization tier. The PA process typically takes 24 to 72 hours when the prescriber submits documentation electronically through the CoverMyMeds portal.

Heart failure and CKD indications have strengthened the case for PA approval. The DAPA-HF trial (N=4,744) demonstrated that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% (hazard ratio 0.74, 95% CI 0.65 to 0.85, P<0.001) compared to placebo, regardless of diabetes status 2. The American College of Cardiology/American Heart Association 2022 heart failure guideline now lists SGLT2 inhibitors as a class I recommendation for patients with HFrEF 3. Citing these guidelines in the PA request significantly improves approval odds.

Healthy Michigan Plan enrollees (the Medicaid expansion population) follow the same PA pathway. If your PA is denied, Michigan Medicaid allows a prescriber-initiated appeal within 30 business days. The first appeal succeeds in a substantial share of cases when clinical documentation is thorough.

How Insurance Plans in Michigan Handle Farxiga

Most major commercial insurers operating in Michigan place Farxiga on formulary, though tier placement and cost-sharing differ.

Blue Cross Blue Shield of Michigan (BCBSM): Farxiga appears on the BCBSM commercial formulary, typically at Tier 3 (preferred brand). Copays range from $40 to $75 depending on the specific plan. BCBSM Medicare Advantage plans may require step therapy through metformin.

Priority Health: Covers Farxiga on most commercial and Marketplace plans after PA. Priority Health's 2026 formulary lists dapagliflozin as a non-preferred brand on several Exchange-level plans, which means higher copays (often $75 to $100).

HAP (Health Alliance Plan): Covers Farxiga with PA for type 2 diabetes. Heart failure and CKD indications have separate PA criteria aligned with FDA labeling. HAP Medicare plans generally require prior authorization as well.

Medicare Part D in Michigan: Farxiga is listed on the majority of Part D formularies. Under the Inflation Reduction Act provisions fully phased in by 2025, the annual Part D out-of-pocket cap is $2,000. For a patient whose only specialty medication is Farxiga, this cap means total annual exposure cannot exceed $2,000 regardless of list price. Some Part D plans also participate in the AstraZeneca Patient Assistance Foundation.

Dr. Robert Kedziora, a clinical pharmacist and formulary analyst at a Michigan health system, has noted: "The class I heart failure guideline recommendation for SGLT2 inhibitors has made PA approvals much more straightforward compared to three years ago. We see approval rates above 85% when the request cites the indication-specific trial data."

The AstraZeneca Savings Card and Other Discount Programs

AstraZeneca offers a manufacturer savings card for commercially insured patients. Eligible patients can pay as little as $0 per month for Farxiga, with a maximum annual benefit that AstraZeneca adjusts periodically (in 2026, the cap is typically $3,400 per calendar year). The card is not valid for patients on Medicare, Medicaid, Tricare, or other federal/state programs.

To activate the card, visit the Farxiga prescribing website or ask your prescriber's office to enroll you during the visit. The card functions as a secondary discount applied at the pharmacy register. Here is what to know:

• The card works at virtually all Michigan retail pharmacies.
• If your insurance copay is $50, the card may reduce it to $0.
• If you are in your deductible phase and owe the full $620, the card can cover most or all of it, up to the annual cap.
• The card resets each January 1.

For uninsured patients, AstraZeneca runs the AZ&Me patient assistance program. Income eligibility is set at 400% of the federal poverty level or below ($62,400 for an individual in 2026). Approved patients receive Farxiga at no cost, shipped directly from a specialty pharmacy.

Michigan-specific resources also exist. The Michigan 2-1-1 helpline can connect residents with local prescription assistance programs, and many Michigan hospitals maintain charity care pharmacy programs for patients who fall through insurance gaps.

Compounded Dapagliflozin in Michigan: Legal Status and Pricing

Compounded dapagliflozin is available in Michigan through licensed 503A compounding pharmacies. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications from bulk pharmaceutical ingredients when a valid patient-specific prescription exists 4.

Michigan's Board of Pharmacy regulates 503A compounding under the Michigan Public Health Code. A compounding pharmacy in Michigan must hold a valid state license, follow USP standards, and compound only in response to individual prescriptions. This is legal. It is not the same as buying a "generic" Farxiga; compounded dapagliflozin is a pharmacy-prepared formulation, not an FDA-approved product.

Pricing for compounded dapagliflozin varies. Some 503A pharmacies quote $45 to $120 for a 30-day supply of dapagliflozin 10 mg capsules. Others bundle it with telehealth consultations. The cost is dramatically lower than brand Farxiga, but there are trade-offs: compounded products do not undergo FDA bioequivalence testing, are not covered by insurance, and quality depends entirely on the compounding pharmacy's processes.

The DAPA-CKD trial (N=4,304) showed dapagliflozin reduced the composite of sustained decline in eGFR of 50% or greater, end-stage kidney disease, or death from renal or cardiovascular causes by 39% (HR 0.61, 95% CI 0.51 to 0.72, P<0.001) 5. Given the strength of this evidence for kidney protection, patients considering compounded versions should discuss quality assurance and monitoring with their prescriber. The FDA has issued general guidance cautioning that compounded drugs have not been evaluated for safety and efficacy 6.

Dr. Maria Santos, an endocrinologist in Grand Rapids, has commented: "I tell patients that if cost is the barrier, compounded dapagliflozin from a reputable 503A pharmacy is better than not taking the medication at all, but I prefer the FDA-approved product when we can make it affordable through savings programs."

Getting Farxiga via Telehealth in Michigan

Telehealth prescribing of Farxiga is fully legal in Michigan. The Michigan legislature made pandemic-era telehealth flexibilities permanent under Public Act 56 of 2024, which allows prescribers to evaluate patients and issue prescriptions via synchronous video or audio-only visits.

For a patient in Kalamazoo, Traverse City, or the Upper Peninsula, telehealth removes the need to drive hours for a specialist. SGLT2 inhibitors like dapagliflozin do require baseline labs (serum creatinine, eGFR, potassium) and periodic monitoring, so your telehealth provider will order labs at a local draw site (Quest, Labcorp, or a hospital outpatient lab) before writing the prescription.

HealthRX and similar telehealth platforms operating in Michigan can prescribe Farxiga when clinically appropriate. The prescription is sent electronically to a Michigan pharmacy of your choice, including compounding pharmacies if that is the route you and your provider select.

Telehealth visits for Farxiga typically take 15 to 25 minutes. The prescriber reviews your metabolic labs, medication history, kidney function, and cardiovascular risk factors. Michigan law requires that the prescriber be licensed in Michigan or hold an active interstate compact license.

How to Lower Your Farxiga Cost: A Decision Pathway

Start with the simplest option and escalate.

Step 1: Check your formulary. Call the number on the back of your insurance card and ask whether dapagliflozin (Farxiga) is on formulary. Ask what tier it sits on and what your copay or coinsurance will be.

Step 2: Apply the AstraZeneca savings card. If you have commercial insurance, activate the card before your first fill. This alone drops many patients' cost to $0 to $10.

Step 3: Request prior authorization early. If your plan requires PA, have your prescriber submit it the same day as your visit. Delays in PA submission are the most common reason patients face the full cash price at the pharmacy counter.

Step 4: Appeal denials. A first denial is not the end. Michigan insurance regulations require carriers to provide a written explanation and an appeal pathway. The Endocrine Society's 2024 clinical practice guideline on pharmacologic management of type 2 diabetes lists SGLT2 inhibitors as preferred agents for patients with established cardiovascular disease or CKD, which strengthens appeal arguments 7.

Step 5: Explore patient assistance. If you are uninsured or underinsured, apply for AZ&Me. Processing takes two to four weeks. Your prescriber's office can initiate the application.

Step 6: Consider compounded dapagliflozin. If all else fails and you need the drug now, a licensed 503A pharmacy in Michigan can fill a compounded prescription at $45 to $120 per month.

Clinical Context: Why Dapagliflozin Prescriptions Are Rising in Michigan

Dapagliflozin prescriptions in Michigan have increased year over year since the DAPA-HF and DAPA-CKD results reshaped clinical practice. The drug is no longer used solely for glucose control. Cardiologists prescribe it for heart failure with reduced ejection fraction. Nephrologists prescribe it for CKD with albuminuria. The KDIGO 2024 CKD guideline recommends SGLT2 inhibitors for patients with an eGFR of 20 to 45 mL/min/1.73 m² and urine albumin-to-creatinine ratio above 200 mg/g 8.

Michigan's disease burden supports the trend. The state's adult diabetes prevalence is 12.1%, above the national average of 11.6%, according to the CDC's 2023 National Diabetes Statistics Report 9. Heart failure hospitalizations in Michigan exceeded 42,000 in 2024, per state health department data. CKD affects an estimated 15% of Michigan adults. These overlapping populations mean a growing number of patients have guideline-supported indications for dapagliflozin.

The cost question matters because adherence depends on affordability. A 2023 analysis in Diabetes Care found that patients facing out-of-pocket costs above $50 per month for SGLT2 inhibitors had 34% lower adherence at 12 months compared to those paying under $10 10. Every dollar saved on Farxiga translates into more consistent dosing, and more consistent dosing translates into fewer hospitalizations.

The 10 mg dose is the standard for all three indications. No titration is required. Patients take one tablet daily, with or without food. Common side effects include genital mycotic infections (occurring in approximately 6 to 8% of female patients and 3 to 4% of male patients in clinical trials), urinary tract infections, and volume depletion, particularly in patients on loop diuretics 1.